1. Six months after Pfizer announced its plans to acquire Biohaven Pharmaceuticals, the deal finalized Oct. 3 for $11.6 billion. One of Biohaven’s biggest assets is its portfolio of migraine brand-name drugs, including Nurtec and Vydura.
2. The pharmaceutical company’s late-stage clinical trial of talazoparib and enzalutamide delivered “topline results” among men with metastatic castration-resistant prostate cancer. Together, the treatments improved radiographic progression-free survival rates, according to an Oct. 4 news release. Pfizer said it is still analyzing secondary endpoints.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
